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The bcl-2 gene is one of a complex group of genes which control programmed cell death. Bcl-2 acts to extend cell survival by
blocking apoptosis, and thereby may inﬂuence tumour prognosis. This study of 187 high grade gliomas reviews
clinicopathological prognostic features and the relationship to bcl-2 expression. Bcl-2 immunostaining was assessed in 159
specimens from these patients, by scoring systems of 0 to 3 for intensity of scoring and proportion of cells staining. Age,
histology, pre- and post-operative performance status were found to be strongly predictive of survival (log rank test P50.0001).
The type of surgery performed did not inﬂuence survival in this group of patients. The expression of bcl-2 had a signiﬁcant
relationship with survival (univariate Cox model P=0.0302, hazard ratio 0.8, 95% conﬁdence interval 0.65–0.98), with increased
staining associated with improved survival. Multivariate analysis showed performance status, histology and proportion of cells
staining for bcl-2 to be independently predictive of survival. Bcl-2 staining was not related to histological grade of tumours.
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Gliomas form the most common group of primary brain tumours,
accounting for 40% of all CNS neoplasms. Malignant gliomas (glio-
blastoma multiforme and anaplastic astrocytomas) are most
common and carry the worst prognosis. However, malignant glio-
mas are a heterogeneous group of neoplasms, with a varied
survival. Accurate identiﬁcation of the factors inﬂuencing prognosis
in malignant gliomas is important in selecting appropriate treatment
and in evaluating its effectiveness. Moreover, the investigation of
factors associated with particular prognosis may elucidate the under-
lying biological mechanisms involved in the development or
progression of the tumour. Bcl-2 is one of a family of interacting
proteins involved in the regulation of controlled cell death, apoptosis
(Korsmeyer, 1992; McDonnell et al, 1996). Bcl-2 appears to protect
against apoptosis by preventing cells from responding to stimuli to
initiate apoptosis. The bcl-2 protein forms homo- and hetero-dimers
with another protein in this family, Bax. The ratio of activity of the
pro-apoptotic Bax to the anti-apoptotic bcl-2 determines the
response to apoptotic stimuli; a decrease in the ratio of bcl-2 to
Bax protein renders cells more vulnerable to apoptosis (Oltvai et
al, 1993). P53 acts to cause this effect (Miyashita et al, 1994).
Radiation and chemotherapy exert their effects largely through
the induction of apoptosis, so excessive bcl-2 activity may render
them less effective. Apoptosis is a recognised feature of malignant
glioma (Ellison et al, 1995), but the relationship of bcl-2 expression
to this is unclear. Increasing numbers of apoptotic bodies have
been shown to correlate with increasing grade of malignancy in
gliomas (Ellison et al, 1995). However, whether bcl-2, as a protec-
tor from apoptosis, shows an inverse relationship to this is
indeterminate, with conﬂicting results (Nakasu et al, 1994; Krishna
et al, 1995; Weller et al, 1995). It is also unclear whether bcl-2
expression relates to grade of CNS tumours, though there are
suggestions that it may. Nakasu et al (1994) and Ehrmann
(1997) both found lower grade tumours to have higher bcl-2
expression, but other groups have failed to conﬁrm these results
(Schiffer et al, 1996; Newcomb et al, 1997, 1998).
In malignant glioma inherent prognostic features appear to exert
a much stronger inﬂuence on survival than treatment effects. Age
in particular seems to have an overriding effect on survival, inde-
pendent of other factors (Burger and Green, 1987; MRC
Working Party, 1990). Duration of symptoms, performance status,
presence and duration of ﬁts as a ﬁrst symptom, and degree of
neurological impairment at presentation have all been recognised
as factors which inﬂuence prognosis (Cohaden et al, 1985; MRC
Working Party, 1990; Hutton et al, 1992). In addition, the prog-
nostic signiﬁcance of the extent of surgical resection has been
identiﬁed in several series (MRC Working Party, 1990; Devaux et
al, 1993), and histological grade and features, in particular necrosis,
appear to be major prognostic determinants (Cohaden et al, 1985;
Seung Kim et al, 1991; Salmon et al, 1994).
This study therefore aimed to evaluate the prognostic effect of
bcl-2 in the context of a patient population where these inherent
factors are well characterised.
MATERIALS AND METHODS
Edinburgh provides a tertiary referral centre for neuro oncology
with a multidisciplinary unit which was established in 1987. Three
hundred and ﬁfty-six patients were seen in the ﬁrst 6 years, and
none have been lost to follow-up. This group represents approxi-
mately 60% of the incident cases diagnosed in the geographical
area covered by the unit. A database of all patients referred to
the neuro oncology unit was established, collecting information
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status (KPS), pathological diagnosis, treatment and subsequent
follow up. The management policy for malignant gliomas in the
unit is for maximal surgical resection compatible with safety,
followed by radiotherapy to the initial tumour site with generous
margins. For high grade tumours the dose used is 60 Gy in 30 daily
fractions over 6 weeks. Chemotherapy is not used routinely in the
primary or adjuvant setting, but is used for selected patients at
relapse, usually as part of a clinical study.
Surgical biopsy specimens from the 187 high grade glioma patients
diagnosedsince1987wereretrievedfromtheﬁlesoftheNeuropathol-
ogy Laboratory, Edinburgh. Of these, there was sufﬁcient material in
159 cases to allow additional investigations to be performed and these
cases were then reviewed using the WHO Classiﬁcation (Kleihues et
al, 1993) in relation to the earlier diagnosis and entered into the study
(79 glioblastoma and 80 anaplastic astrocytomas). From the surgical
blocks, sections were stained by haemotoxylin and eosin for review
and most of the cases had the diagnosis conﬁrmed using immunocy-
tochemistry for glial acidic protein (DAKO, UK) in a standard
immunoperoxidase technique. Sections were chosen toberepresenta-
tive of tumour rather than containing large numbers of reactive cells.
Immunostaining for bcl-2 was performed by a standard ABC method
using a mouse anti-human bcl-2 primary antibody. A normal tonsil
was used as a positive control, and a negative control with omission
of the primary antibody.
Immunostaining was assessed by semiquantitative scoring
systems for percentage of cells staining and intensity of staining.
Both were scored on scales of 0 to 3. For percentage of cells stain-
ing, a score of 0 represented no cells staining, a score of 1
represented less than 25%, a score of 2, 25 to 50%, and a score
of 3 over 50% of cells staining. To establish a scale for intensity
of staining an initial pilot group of sections was examined to
observe the range of staining. A semiquantative scale of 0 to 3
was then used to assess the intensity of staining. See Figure 1 for
example of staining scores.
Gliomas are often heterogeneous in their composition, and
where bcl-2 staining was variable an attempt was made to give
an overall representative score. The sections were scored by two
observers (FE McDonald and JW Ironside), blind to other data.
Statistical methods
Descriptive analysis was ﬁrstly performed on the clinical data.
Kaplan–Meier plots of survival were produced, and the logrank
test performed. As bcl-2 staining intensity and proportion are both
ordered values, trend analysis using univariate Cox models was
performed. Multivariate analysis by backward stepwise Cox regres-
sion analysis was then performed to explore the combined effect of
these variables on survival (Cox and Oakes, 1984)
RESULTS
Patient characteristics
This study examined 187 high grade gliomas. The mean age was 51
years (s.d. of 13.6), range 8 to 75 years. The mean age of patients
with glioblastoma multiforme was 54.5 years, and of anaplastic
astrocytoma 48 years. Sixty-one per cent of ‘high grade’ patients
were male and 31% female.
Sixty-eight patients had a biopsy of the tumour, 31 had a
macroscopically complete resection, 86 had a partial resection.
All except six had post-operative radiotherapy (Table 1).
ThemeanageofpatientswithKarnofskyperformancestatus(KPS)
90was38.6years(s.d.10.6),KPS80was53.7years(s.d.11.7)andKPS
70 or less was 57.1 years (s.d. 9.9), suggesting age and performance
status are closely linked. Patients with glioblastoma multiforme
had a slightly worse pre and post operative performance status
(mean KPS 58.76 and 76.53 respectively) compared to anaplastic
astrocytoma patients (mean KPS 65.59 and 81.48 respectively).
Bcl-2 analysis
Bcl-2 staining intensity did not appear to have any signiﬁcant rela-
tionship to the other clinicopathological variables; in particular it
did not seem to be related to tumour grade (Fisher’s Exact
P=0.443). Proportion of cells staining also did not show any signif-
icant relationship to the other variables, including histology
(Fisher’s Exact P=0.612).
Survival analysis
Survival was analysed with respect to all the collected variables. The
median overall survival for the group was 10.3 months. The
median progression free survival was 6.4 months. For glioblastoma
multiforme patients the mean progression free survival was 6.8
months and overall survival was 10.1 months. For anaplastic astro-
cytomas the mean progression free survival was 19 months and
overall survival was 24.7 months (Figure 2). The inﬂuence of post
operative performance status on survival is marked. The mean
progression free survival for patients with KPS 90 was 29.8 months,
for patients with KPS 80 was 10.4 months, and for patients with a
KPS 70 or less 4.2 months (Figure 3).
The log rank test identiﬁed age as a strongly statistically signiﬁ-
cant predictor of survival (Figure 4), with P50.0001 for both
overall and progression-free survival. Histology and both pre- and
post-operative performance status were also strongly predictive for
survival with P values of 50.0001. In contrast the type of surgery
was not a statistically signiﬁcant predictor of survival, with P values
of 0.36 for overall survival and 0.61 for progression-free survival.
Univariate Cox models showed a statistically signiﬁcant relation-
ship between the proportion of cells staining for bcl-2 and overall
survival, with a P value of 0.0302. This model gave a hazard ratio
of 0.8 (95% conﬁdence interval 0.65–0.98), so a higher proportion
staining is associated with a better prognosis (Figure 5). There did
not seem to be a relationship to progression free survival however
(P40.1). The models did not show any signiﬁcant relationship
between the intensity of staining and either overall or progression
free survival (P values 40.1).
Multivariate analysis
Cox’s regression analysis was performed on all ﬁve clinical variables
with respect to overall survival. This identiﬁed histology and post-
operative performance status as independent important predictors
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Figure 1 Examples of Bcl-2 immunostaining scoring systems.
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anaplastic astrocytoma gave a hazard ratio of 0.41 with 95% conﬁ-
dence interval of 0.26 to 0.65 and P value 50.001. Post-operative
performance status 470 vs 80 gave a hazard ratio of 0.34 with 95%
conﬁdence interval 0.22 to 0.54 and P value 50.001 for overall
survival. Post-operative performance status 470 vs 90 gave a
hazard ratio 0.08 with 95% conﬁdence interval 0.04 to 0.15 and
P value 50.001.
For progression-free survival the same two variables were iden-
tiﬁed. Histology gave a hazard ratio of 0.41 with 95% conﬁdence
interval 0.26 to 0.64 and P value 50.001. Post-operative perfor-
mance status 470 vs 80 gave a hazard ratio of 0.29 with 95%
conﬁdence interval 0.18 to 0.46 and P value 50.001. Post-opera-
tive performance status 470 vs 90 gave a hazard ratio of 0.08
with 95% conﬁdence interval 0.04 to 0.16 and P value 50.001.
Post-operative performance status and age were found to be highly
correlated, so it is likely that the effect of age is hidden by the
inﬂuence of performance status.
Bcl-2 staining was then included in the Cox modelling (Table 2).
The resulting model produced similar conclusions in relation to the
clinical variables, but in addition identiﬁed the proportion of cells
staining for bcl-2 as a statistically signiﬁcant independent predictor
of overall but not progression free survival. The hazard ratio for
bcl-2 proportion treated as a continuous variable was 0.75 with
95% conﬁdence interval 0.57–0.99, and P value 0.043. Intensity
of bcl-2 staining did not appear to be predictive of survival.
DISCUSSION
In common with other groups, multivariate analysis of the clinical
and histological data identiﬁed tumour grade and performance
status as independently signiﬁcant prognostic factors. In addition,
in univariate analysis, age was identiﬁed as a strongly signiﬁcant
predictor of survival, but the close correlation with performance
status seems to have masked this effect in multivariate analysis.
This study conﬁrms the predictive value of the WHO grading
system. The type of surgery performed did not predict survival
in this group of patients, however.
Analysis of bcl-2 staining showed that the proportion of cells
staining was independently predictive of survival, but that the
intensity was of no prognostic value. This intensity of staining
result may reﬂect several factors. It is possible that the variability
in intensity of staining is an artefact of staining technique, which
may depend on variables in tissue preservation, ﬁxation etc.,
although all specimens were processed in a standard way in the
Neuropathology Laboratory.
The proportion of cells staining correlated with the overall
(though not progression free) survival, with greater staining
predicting longer survival. It was particularly interesting that this
was independent of histology.
A common limitation of studies on gliomas is that biopsies may
be small and unrepresentative because of tumour heterogeneity. In
addition, there may be a further sampling error when blocks are
chosen for staining. In this study it was noted that seven of the
sections were particularly small and may not be representative. A
further possible criticism is that no attempt was made to distin-
guish the type of cells, neoplastic or reactive, which were
positively staining.
Several previous studies have also examined bcl-2 staining in
gliomas. Newcomb et al (1998) examined several growth control
genes including bcl-2 in 80 patients with glioblastoma multi-
forme. They used a similar four step score to assess the
frequency of immunopositive cells, but only analysed by positive
verses negative staining. They found no difference in survival
according to bcl-2 staining. Ehrmann et al (1997) looked at
bcl-2 immunohistochemical expression in 42 patients with astro-
cytomas, of which 23 were malignant gliomas. Again a scoring
system was used, but analysis was based on positive vs negative
staining. In this small group no relationship to overall survival
was found, although higher bcl-2 staining was noted in lower
grade tumours. Schiffer et al (1996) examined bcl-2 expression
in 100 CNS tumours, which included 21 grade 3 or four
tumours, and found no correlation with survival in each tumour
type.
Newcomb et al (1997) also assessed bcl-2 expression, relating it
to survival and p53 expression in 58 astrocytomas from 21 paedia-
tric patients and 37 adult patients. They found no relationship
between bcl-2 staining and survival in the paediatric patients, but
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Table 1 Patients survival in relation to clinical variables
No. of events Median survival (years)
Variable Classiﬁcation No. of patients Deaths Relapses Overall Progression free
Age (years) 535 27 17 20 3.1 2.5
35–44 25 16 16 2.0 1.6
45–60 83 77 77 0.8 0.5
460 52 50 49 0.5 0.4
Histology Glioblastoma multiforme 88 85 84 0.6 0.4
Anaplastic astrocytoma 99 75 78 1.5 0.8
Surgery Biopsy 68 59 58 0.6 0.5
Partial resection 86 74 75 0.9 0.5
Macroscopic resection 31 25 27 1.3 0.7
Pre-operation Karnofsky performance status 450 30 30 29 0.4 0.3
60 63 61 58 0.7 0.5
570 47 30 36 2.0 1.1
Post-operation Karnofsky performance status 470 37 37 36 0.5 0.3
80 59 56 55 1.0 0.6
90 30 15 20 3.5 2.4
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Figure 2 Inﬂuence of histology on overall survival.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(12), 1899–1904found the bcl-2 negative WHO grade IV tumours in adults had a
shorter median survival. Our study examined a larger group of
malignant gliomas, giving more statistical power to detect survival
effects within this group than these other studies.
Strik et al (1999) looked at bcl-2 expression in 37 cases of glio-
blastoma multiforme at ﬁrst resection and then again at recurrence.
They found bcl-2 positivity in a high percentage of initial (91%)
and recurrent tumours (97%). They suggest that a shift in the
bcl-2 rheostat may lead to resistance to apoptosis, but found this
in both patients treated with radiotherapy with or without
chemotherapy, and in patients who had received no treatment, in
favour of natural resistance to apoptosis rather than acquired resis-
tance due to the selective pressures of therapy. They also found
that patients with initial negative or weak bcl-2 expression had a
trend to better prognosis than those with an intermediate or strong
bcl-2 expression (12 vs 8 months median progression free survival),
though this result was not statistically signiﬁcant in their small
group of patients.
The ﬁnding that increased bcl-2 staining confers a survival
advantage is contrary to much of our understanding of bcl-2. Bcl-
2 prevents apoptosis, and may thereby cause neoplastic cell popula-
tion expansion. Increased bcl-2 expression would therefore be
expected to confer a worse prognosis. In addition, radiotherapy
and chemotherapy induce apoptotic cell death, and an excess of
bcl-2 should render them less effective. Bcl-2 does not prevent
chemotherapy induced cell cycle arrest, but prolongs survival during
this period, so that on withdrawal of the drug proliferation can
resume. Thus it changes the drug from being cytotoxic to cytostatic.
Chemotherapeutic agents also damage DNA and bcl-2 prevents this
from leading to cell death, allowing mutations to persist.
It has long been recognised that glioblastomas have frequent
apoptotic bodies. Ellison et al (1995) correlated apoptotic index
with increasing grade of malignancy, and rate of proliferation
assessed by Ki-67 labelling. They found higher bcl-2 staining in
lower grade tumours. There was a trend for apoptotic index to
be lower in bcl-2 positive than negative tumours, but this was
non signiﬁcant. They also examined the interaction of bcl-2 with
the promoter of apoptosis, p53. From their results they hypothe-
sised that upregulation of bcl-2 is an advantage in tumours
where increased wild type p53 promotes apoptosis in response to
DNA damage, but where p53 is disabled, this upregulation of
bcl-2 is not required to increase tumour growth. Alderson et al
(1995) produced some evidence to support this theory, showing
bcl-2 expression was more common in gliomas with wild type
p53. Newcomb et al (1997) failed to conﬁrm this in their series
of gliomas, however.
In other tumours bcl-2 positivity has not been clearly correlated
with tumour aggressiveness. In prostate cancer it appears to be a
late event, occurring with androgen independence (McDonnell et
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Figure 3 Inﬂuences of histology and post-operative Karnofsky performance status on progression free survival.
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Figure 4 Inﬂuence of age on overall survival.
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Figure 5 Inﬂuence of proportions of cells staining for bcl-2 on overall
survival.
Table 2 Cox’s Regression model including proportion of cells staining for
bcl-2
Variable Classiﬁcation
Hazard
ratio
95% conﬁdence
interval P value
Age Decades
(continuous)
1.3 1.04–1.63 0.023
Histology GBM vs AA 0.37 0.23–0.59 50.001
Post-operative 470 vs 580 0.39 0.24–0.63 50.001
performance status 480 vs 90 0.3 0.15–0.6 50.001
Proportion staining Continuous 0.75 0.57–0.99 0.043
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cancer it appears to be an early event (Hague et al, 1994; Joensuu
et al, 1994; Leek et al, 1994). In neuroblastoma bcl-2 expression
seems to correlate with the morphology and differentiation of
neuroblastoma cells in vitro, greater bcl-2 expression being asso-
ciated with more neuroblastic cells (Reed et al, 1991).
Studies in, for example, myeloid leukaemia, carcinoma of pros-
tate and large cell Non Hodgkins lymphoma, have found bcl-2
expression to be associated with a poor response to treatment,
and a shorter disease free and overall survival (Colombel, 1993;
Reed et al, 1996). However, Silvestrini et al (1994), found bcl-2
expression to correlate with a good prognosis in breast cancer.
Reed et al (1996) discussed this paradoxical result, hypothesising
that it is a reﬂection of the complex interaction between the family
of genes which control apoptosis, and in particular the ratio of
activity of the proapoptotic gene Bax to the anti apoptotic bcl-2.
A decrease in the ratio of bcl-2 to Bax protein renders cells more
vulnerable to apoptosis (Borner, 1996). P53 acts to cause this effect
and other members of the bcl-2 family also act in concert. Reed et
al (1996) suggest that in Silvestrini’s group of patients reductions
in bcl-2 were tolerated because of diminished Bax protein, keeping
the ratio in favour of apoptosis, and conferring a good prognosis.
Krawejski et al (1995) showed that loss of BAX expression was
strongly associated with loss of bcl-2 immunopositivity in a small
group of metastatic breast cancer patients. Reduced Bax (and
bcl-2) immunostaining was associated with poor responses to
chemotherapy and shorter overall survival. Similarly, in cervical
cancer, Crawford et al (1998) found that bcl-2 was associated with
a better 5 year survival. They found p53 positivity was associated
with a survival disadvantage but Bax was not predictive of survival
in their group of patients.
In our study bcl-2 staining was associated with better survival.
We would hypothesise that this reﬂects interaction between bcl-2
and the other factors controlling apoptosis. It would therefore be
of interest to examine Bax and p53 expression in this group of
patients to further clarify these interactions. If therapeutic mani-
pulations of the apoptotic pathway are to be effective then the
complexity of the pathway and the interacting members must be
considered.
In conclusion, this study reviewed the prognostic factors in high
grade glioma and found, in common with previous studies, that
age, performance status and histology are predictive of
survival. We have identiﬁed the proportion of cells staining for
bcl-2 as a statistically signiﬁcant prognostic factor in high grade
glioma, independent of histological grade. This ﬁnding warrants
further investigation, both to conﬁrm this result in another group
of patients and to elucidate the underlying mechanisms inﬂuencing
glioma cell apoptosis.
ACKNOWLEDGEMENTS
We are grateful to Mrs E Wyatt for laboratory assistance, and to Mr
R Rye and especially Moira Stewart for statistical analysis. We are
grateful to the Brain Tumour Research Fund for supporting the data
collection, the ICRF Bioinformation Unit for designing the compu-
terised database, and to Joanna Hadley and Henry Potts from the
Medical Statistics Group of the ICRF for statistical analysis.
REFERENCES
Alderson LM, Castleberg RL, Harsh GR, Louis DN, Henson JW (1995)
Human gliomas with wild type p53 express bcl-2. Cancer Res 55: 999–
1001
Borner C (1996) Diminished cell proliferation associated with the death-
protective activity of bcl-2. J Biol Chem 271(22): 12695–12698
Burger BC, Green S (1987) Patient age, histological features, and length of
survival in patients with glioblastoma multiforme. Cancer 59: 1617–1625
Cohaden F, Aouad N, Rougier A, Vital C, Rivel C, Dartigues JF (1985) Histo-
logic and non-histologic factors correlated with survival time in
supratentorial astrocytic tumours. J Neuro-Oncology 3: 105–111
Colombel M, Symmans F, Gil S, O’Toole KM, Chopin D, Benson M, Olsson
CA, Korsmeyer S, Buttyan R (1993) Detection of the apoptosis suppressing
oncogene bcl-2 in hormone refractory human prostate cancer. Am J Pathol
143: 390–400
Cox DR, Oakes D (1984) Analysis of survival data. London: Chapman and
Hall
Crawford RAF, Caldwell C, Iles RK, Lowe D, Shepherd JH, Chard T (1998)
Prognostic signiﬁcance of the bcl-2 apoptotic family of proteins in primary
and recurrent cervical cancer. Br J Cancer 78: 210–214
Devaux BC, O’Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in
malignant glial neoplasms. J Neurosurg 78: 767–775
Ehrmann Jr J, Kolar Z, Vojtesek B, Kala M, Komenda S, Oulton A (1997)
Prognostic Factors in astrocytomas: Relationship of p53, MDM-2, Bcl-2
and PCNA immunohistochemical expression to tumor grade and overall
patient survival. Neoplasia 44: 299–304
Ellison DW, Seart PV, Gatter KC, Weller RO (1995) Apoptosis in cerebral
astrocytic tumours and its relationship to expression of the bcl-2 and
p53 proteins. Neuropath Applied Neurobiol 21: 352–361
Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C (1994) Bcl-2
expression in human colorectal adenomas and carcinomas. Oncogene 9:
3367–3370
Hutton JL, Smith DF, Sandemann D, Foy PM, Shaw MDM, Williams IR,
Chadwick DW (1992) Development of prognostic index for primary
supratentorial intracerebral tumours. J Neurol, Neurosurg Psychiat 55:
271–274
Joensuu H, Pylkkanen L, Toikkanen S (1994) Bcl-2 protein expression and
long term survival in breast cancer. Am J Pathol 145: 1191–1198
Kleihues P, Burger PC, Sheithauer BW (1993) Histological Typing of Tumours
of the Central Nervous System: World Health Organisation International
Histological Classiﬁcation of Tumours, Berlin: Springer
Korsmeyer S (1992) Bcl-2 initiates a new category of oncogenes: regulators of
cell death. Blood 80: 879–886
Krajewski S, Blomvqvist C, Franssila K, Krajewska M, Wasenius V-M, Niska-
nen E, Reed JC (1995) Reduced expression of the pro-apoptotic gene Bax is
associated with poor response rates to combination chemotherapy and
shorter survival in women with metastatic breast adenocarcinoma. Cancer
Res 55: 4471–4478
Krishna M, Smith TW, Recht LD (1995) Expression of bcl-2 in reactive and
neoplastic astrocytes: lack of correlation with presence or degree of malig-
nancy. J Neurosurg 83: 1017–1022
Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL (1994) Bcl-2 in
normal human breast and carcinoma, association with oestrogen receptor
positive, epidermal growth factor negative tumours and in situ cancer. Br J
Cancer 69: 135–139
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hseih
JT, Tu SM, Campbell ML (1992) Expression of the proto-oncogene bcl-
2 in the prostate and its association with the emergence of androgen-inde-
pendent prostate cancer. Cancer Res 52: 6940–6944
McDonnell TJ, Beham A, Sarkiss M, Anderson MM, Lo P (1996) Importance
of the Bcl-2 family in cell death regulation. Experentia 52: 1008–1017
Miyashita T, Krajewski S, Krajewski M, Wang HG (1994) Tumor suppressor
p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo.
Oncogene 9: 1799–1805
MRC: A report of the Medical Research Council Brain Tumour Working
Party (1990) Prognostic factors for high grade malignant glioma: Develop-
ment of a prognostic index. J Neuro-Oncol 9: 47–55
Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J (1994) Bcl-2 protein
expression in tumours of the central nervous system. Acta Neuropathol
88: 520–526
Newcomb E, Bhalla SK, Parrish CL, Hayes RL, Cohen H, Miller DC (1997)
Bcl-2 protein expression in astrocytomas in relation to patient survival
and p53 gene status. Acta Neuropathol 94: 369–375
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Prognostic influence of bcl-2 in malignant glioma
FE McDonald et al
1903
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(12), 1899–1904Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC
(1998) Survival of patients with glioblastoma multiforme is not inﬂuenced
by altered expression of P16, p53, EGFR, MDM2 or Bcl-2 genes. Brain
Pathol 8: 655–667
Oltvai Z, Milliman C, Kersmeyer SJ (1993) Bcl-2 heterodimerises in vivo with
a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:
609–619
Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D (1991)
Differential expression of bcl-2 protooncogene in neuroblastoma and other
human tumour cell lines of neural origin. Cancer Res 51: 6529–6538
Reed JC, Miyashita T, Takayama S, Hong-Gong W, Sato T, Krawjewski S,
Aime-Sempe C, Bodrug S, Kitada S, Hanada M (1996) Bcl-2 family
proteins: Regulators of cell death in the pathogenesis of cancer and resis-
tance to therapy. (Review). J Cell Biochem 60: 23–32
Salmon I, Dewitte O, Pasteels J-L, Flament-Durand J, Brotchi J, Vereerstrae-
ten P, Kiss R (1994) Prognostic scoring in adult astrocytic tumors using
patient age, histopathological grade, and DNA histogram type. J Neurosurg
80: 877–883
Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiado-Piat L (1996) Bcl-2
distribution in neuroepithelial tumors: an immunohistochemical study. J
Neuro-oncol 27: 101–109
Seung Kim T, Halliday AL, Hedley-White T, Convery K (1991) Correlates of
survival and the Daumas-Duport grading system for astrocytomas. J
Neurosurg 74: 27–37
Silvestrini R, Veneroni S, Daidonem M, Benini E, Boracchi P, Mezzetti M,
DiFronzo G (1994) The bcl-2 protein: a prognostic indicator strongly
related to p53 in lymph node negative breast cancer patients. J Natl Cancer
Inst 86: 499–504
Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M,
Meyermann R (1999) Bcl-2 Family protein expression in initial and recur-
rent glioblastomas: modulation by chemoradiotherapy. J Neurol Neurosurg
Psych 67: 763–768
Weller M, Malipeiro U, Agussi A, Reed JC, Fontana A (1995) Protooncogene
bcl-2 gene transfer abrogates Fas/APO-1 Antibody-mediated apoptosis of
human malignant glioma cells and confers resistance to chemotherapeutic
drugs and therapeutic irradiation. J Clin Invest 95: 2633–2643
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Prognostic influence of bcl-2 in malignant glioma
FE McDonald et al
1904
British Journal of Cancer (2002) 86(12), 1899–1904 ã 2002 Cancer Research UK